Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Investors who purchased PennyMac securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly for more information [2]. Group 2: Financial Performance and Stock Impact - On January 29, 2026, PennyMac reported its fourth quarter and full-year 2025 financial results, revealing a significant decline in its servicing segment pretax income to $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the same quarter of 2024 [3]. - The report indicated that pretax income excluding valuation-related items was $47.8 million, reflecting a 70% decrease from the previous quarter, primarily due to increased realization of mortgage servicing rights cash flows driven by lower mortgage rates and higher prepayment activity [3]. - Following the financial report, PennyMac's stock price dropped by $49.78 per share, or 33.3%, closing at $99.92 per share on January 30, 2026 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its success in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Bath & Body Works, Inc. (NYSE: BBWI) is facing a securities fraud lawsuit, with a lead plaintiff deadline set for March 16, 2026, for investors who purchased securities between June 4, 2024, and November 19, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding the company's growth strategy and financial performance [1] - Specific claims include that Bath & Body Works' strategy of pursuing "adjacencies, collaborations and promotions" did not effectively grow the customer base or deliver the expected net sales growth [1] - The lawsuit asserts that as the company's strategy faltered, it relied on brand collaborations to mask weak financial results, leading to a failure to meet previously issued financial guidance [1] Group 2: Legal Representation - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [1] - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions and has recovered hundreds of millions of dollars for investors [1] - The firm emphasizes the importance of selecting qualified legal counsel with experience in securities litigation [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Picard Medical, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on April 13, 2026 [1] Group 1: Class Action Details - Investors who bought Picard Medical securities between September 2, 2025, and October 31, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors wishing to serve as lead plaintiff must file with the Court by April 13, 2026 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Picard's business and operations [5] - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and omission of critical information regarding stock price manipulation [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Enphase Energy, Inc. securities between April 22, 2025, and October 28, 2025, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Enphase securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The lead plaintiff must file a motion with the court by April 20, 2026, to represent other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Allegations - The lawsuit alleges that Enphase made false and misleading statements regarding its ability to manage channel inventory and mitigate the effects of the termination of the Residential Clean Energy Credit [4]. - It is claimed that Enphase overstated its financial and operational prospects, leading to materially false public statements [4]. - The lawsuit asserts that when the true information became public, investors suffered damages [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [4] - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hub Group, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Hub Group securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience and resources [4]. Group 2: Financial Reporting Issues - On February 5, 2026, Hub Group announced a preliminary financial report indicating an error that led to the understatement of purchased transportation costs and accounts payable for the first nine months of 2025, necessitating a restatement of financial statements for the first three quarters of 2025 [3]. - Following the announcement of the financial reporting error, Hub Group's stock price dropped by $9.37 per share, or 18.3%, closing at $41.96 per share on February 6, 2026 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong reputation in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and its founding partner has been recognized as a leading figure in the plaintiffs' bar [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and regulatory challenges [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit claims that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, suggesting confidence in FDA approval despite known concerns from the FDA regarding clinical evidence [5]. - The defendants allegedly communicated misleading information to investors about the likelihood of NDA approval, leading to investor damages when the truth was revealed [5].

What Now: You may be eligible to participate in the class action against Ardent Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by March 9, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All r ...

Core View - The article discusses a securities fraud lawsuit against CoreWeave, Inc. (NASDAQ: CRWV) and highlights the opportunity for investors who purchased securities during the class period from March 28, 2025, to December 15, 2025, to lead the lawsuit [1] Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the court by March 13, 2026, to represent other class members in the litigation [1] - The lawsuit alleges that CoreWeave made false and misleading statements regarding its ability to meet customer demand and the risks associated with its reliance on a single third-party data center supplier [1] Allegations Against CoreWeave - The defendants allegedly overstated CoreWeave's capacity to meet customer demand [1] - The lawsuit claims that the severity of risks related to the third-party data center supplier was materially understated [1] - It is asserted that these misrepresentations were likely to have a significant negative impact on CoreWeave's revenue [1]

securities you may be entitled to compensation without payment of any out of pocket fees or costs through a con...[Back to Newsroom]## Wish your news had this kind of reach?[Sign Up][Learn About Business Wire] Rosen Law Firm Urges Lakeland Industries, Inc. (NASDAQ: LAKE) Stockholders to Contact the Firm for Information About Their RightsFeb 26, 2026 7:46 PM Eastern Standard Time# Rosen Law Firm Urges Lakeland Industries, Inc. (NASDAQ: LAKE) Stockholders to Contact the Firm for Information About Their Rights ...